Pharmacogenomics and migraine: Possible implications

Journal of Headache and Pain

Volumn 9, Issue 1, 2008, Pages 13-18

  Tfelt Hansen, Peer ^a   Brøsen, Kim ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Migraine; Pharmacodynamics; Pharmacogenomics; Pharmacokinetics

Indexed keywords

ALMOTRIPTAN; AMINE OXIDASE (FLAVIN CONTAINING); ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIBN 079BS; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DNA; ELETRIPTAN; G PROTEIN COUPLED RECEPTOR; GLYCERYL TRINITRATE; METHYSERGIDE; MK 0974; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PIZOTIFEN; PLACEBO; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN ANTAGONIST; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

ANALGESIC ACTIVITY; CLINICAL TRIAL; DNA MODIFICATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENETIC VARIABILITY; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG RESISTANCE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; METABOLIC DETOXICATION, DRUG; MIGRAINE DISORDERS; PHARMACOGENETICS; VARIATION (GENETICS);

EID: 39549087024     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-008-0009-y     Document Type: Review

References (61)

1. http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml
2. Giacomini KM, Brett CM, Altman RB, Benowitz WL, Dolan ME, Flockhart DA et al, for the Pharmacogenetic Research Network (2007) The pharmacogenetics research network: From SNP to clinical drug response. Clin Pharmacol Ther 81:328-345
3. Lipton RB, Bigal ME, Stewart WF (2005) Clinical trials of acute treatment for migraine including multiple attacks studies of pain, disability, and health-related quality of life. Neurology 65(Suppl 4):S50-S58
4. Schürks M, Kurth T, Stude P, Rimmbach C, de Jesus J, Jonjic M, Diener H-C, Rosskopf D (2007) G protein β3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther 82:396-401
5. Ophoff RA, van den Maagdenberg AM, Roon KI, Ferrari MD, Frants RR (2001) The impact of pharmacogenetics for migraine. Eur J Pharmacol 413:1-10
6. Lipton RB, Bigal ME, Goadsby PJ (2004) Double-blind clinical trials of oral triptans versus other classes of acute migraine medication - a review. Cephalalgia 24:321-322
7. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT 1B/!D agonists) in acute migraine: A meta-analysis of 53 trials. Lancet 358:1668-1675
8. Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259-1287
9. Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The headaches, 3rd edn. Lippincott, Philadelphia, pp 469-503
10. Tfelt-Hansen P, Bach F, Daugaard D, Tsiropoulos I, Riddersholm B (2006) Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks. A randomised, double-blind, placebo-controlled study. J Headache Pain 7:389-394
11. Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, for the BIBN 4096 BS Clinical Proof of Concept Study Group (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104-1110
12. Dahlöf C, Hogenhuis L, Olesen J, Petit H, Ribbat J, Schoenen J et al (1998) Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: A dose-ranging study. Eur J Neurol 5:469-477
13. Tfelt-Hansen P. The maximum effect of triptans in migraine? A comment. Cephalalgia (in press)
14. Wellington K, Plosker GL (2002) Rizatriptan: An update of its use in the management of migraine. Drugs 62:1539-1574
15. Keam SJ, Goa KL, Figgitt DP (2002) Almotriptan: A review of its use in migraine. Drugs 62:387-414
16. Goadsby PJ, Yates R (2006) Zolmitriptan intranasal: A review of pharmacokinetics and clinical efficacy. Headache 46:138-149
17. US package insert for naratriptan
18. Lacey LF, Hussey EK, Fowler PA (1995) Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 47:543-548
19. Thomsen LL, Dixon R, Lassen LH, Giboens M, Langemark M, Bendtsen L, Daugaard D, Olesen J (1996) 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 16:270-275
20. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones C, Lines CJ, Rapoport AM, On behalf of the MK-0974 Protocol 004 study group (2007) Randomized controlled trial of an oral CGRP antagonist, MK-0974, in the acute treatment of migraine. Neurology [Epub ahead of print]
21. International Headache Society Clinical Trial Subcommittee (2000) Guidelines for controlled trials of drugs in migraine, 2nd edn. Cephalalgia 20:765-786
22. Klapper J, Lucas C, Rosjo O, Charlesworth B, ZODIAC Study Group (2004) Benefits of treating highly disabled migraine patients with zolmitriptan in while pain is mild. Cephalalgia 24:918-924
23. Nett R, Landy S, Schackelford S, Richardson MS, Ames M, Lener M (2003) Pain-free efficacy after treatment with sumatriptan in the mild phase of menstrually associated migraine. Obstet Gynecol 102:835-842
24. Winner P, Landy S, Richardson M, Ames M (2005) Early intervention in migraine with sumatriptan tablets 50 vs 100 mg: A pooled analysis of data from six trials. Clin Ther 27:1785-1794
25. Mathew NT, Kailasam J, Meadors I (2004) Early treatment of migraine with rizatriptan: A placebo-controlled study. Headache 44:669-673
26. Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, Humphrey PPA (1997) Naratriptan: Biological profile in animal models relevant to migraine. Cephalalgia 17:145-152
27. Humphrey PP (2007) The discovery of a new drug class for the acute treatment of migraine. Headache 47(Suppl 1):S10-S19
28. Gupta S, Mehrotra S, Avezaat CJ, Villalon CM, Saxena PR, Massenvandenbrink A (2006) Characterisation of CGRP receptors in the human isolated middle meningeal artery. Life Sci 79:265-271
29. Gupta S, Mehrotra S, Villalon CM,Garreld IM, de Vries R, van Kats JP et al (2006) Characterisation of CGRP receptors in human and pocine isolated coronary arteries: Evidence for receptor heterogeneity. Eur J Pharmacol 530:107-116
30. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R et al (1998) Association of human G protein beta3 subunit variant with hypertension. Nat Genet 18:45-48
31. Rosskopf D, Schurks M, Rimmbach C, Shäfers R (2007) Genetic of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch Pharmacol 374:429-469
32. Serreti A, Artioli P, Quartesan R (2005) Pharmacogenomics in the treatment of depression: Pharmacodynamic studies. Phamacokinet Genomics 15:61-67
33. Mitchell A, Bührman S, Seifert A, Nürnberger J, Wenzel RR, Siffert W et al (2003) Venous response to nitroglycerin is enhanced in young, healthy carriers of the 825T allele of the G protein β3 subunit gene (GNB3). Clin Pharmacol Ther 74:499-504
34. Schürks M, Kurth T, Geiassler, Tessmann G, Diener H-C, Rosskopf D (2007) The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. Cephalalgia 27:363-367
35. Massen VanDenBrink A, Vergouwe MN, Ophoff RA, Naylor SL, Dauwerse HG, Saxena PR, Ferrari MD, Frants RR (1998) Chromosomal localization of the 5-HT1F receptor gene: No evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet 77:415-420
36. Massen VanDenBrink A, Vergouwe MN, Ophoff RA, Saxena PR, Ferrari MD, Frants RR (1998) 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache 38:288-291
37. Mehrotra S, Vanmolkot KR, Frants RR, van den Haagdenberg AM, Ferrari MD, Maassevandenbrink A (2007) The Phe-124-Cys and A-161 T variants of the human 5-HT (1B) receptor gene are not major determinant of the clinical response to sumatriptan. Headache 47:711-716
38. Asuni C, Cherchi A, Congui D, Piccardi MP, Del Zompo M, Stochino ME (2007) Association study between clinical response to mrizatriptan and some candidate genes. J Headache Pain 8:185-189
39. Tfelt-Hansen P, Rolan P (2006) β-Adrenoceptor blocking drugs in migraine prophylaxis. In: Olesen J,Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The headaches, 3rd edn. Lippincott, Philadelphia, pp 519-528
40. Toda N, Tfelt-Hansen P (2006) Calcium antagonists in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The headaches, 3rd edn. Lippincott, Philadelphia, pp 539-544
41. Silberstein SD, Tfelt-Hansen P (2006) Antiepileptic drugs in migraine prophylaxis In: Olesen J, Tfelt-Hansen P, Goadsby PJ, Ramadan NM, Welch KMA (eds) The headaches, 3rd edn. Lippincott, Philadelphia, pp 545-551
42. Evers S, Mylecharane EJ (2006) Nonsteriodal anti-inflammatory and miscellaneous drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The headaches, 3rd edn. Lippincott, Philadelphia, pp 553-565
43. Tfelt-Hansen P. Stricter success criteria. Qualitative and quantitative end points. Acute versus preventive trials In: Olesen J, Ramadan NM (eds) Innovative drug development in headache. International Headache Research Seminar, March 2007 (in press)
44. Tfelt-Hansen P, Saxena PR (2006) Antiserotonin drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The headaches, 3rd edn. Lippincott, Philadelphia, pp 529-537
45. Benito-Leon J, Louis ED (2007) Clinical update: Diagnosis and treatment of essential tremor. Lancet 369:1152-1154
46. Rasmussen BB, Brix TH, Kyvik KO, Brosen K (2002) The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12:473-478
47. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E et al (2006) Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 16:359-367
48. Johnson JA, Herring VL, Wolfe MS, Relling MV (2000) CYP1A2 and CYP2D4 4-hydroxylate propranolol and both exhibit racial differences. J Pharmacol Exp Ther 294:1099-1105
49. Ghobti R, Christensen M, Roh HK, Ingelman-sundberg M, Aklillu E, Bertilsson L (2007) Comparison of CYP1A2 genetic polymorphisms, enzyme activity and genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63:537-546
50. Ismail R, Teh LK (2006) The relevance of CYP 2D6 genetic polymorphism on chronic metoprolol in cardiovascular patients. J Clin Pharmacol Ther 31:99-109
51. Zineh J, BeitelShees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76:536-44
52. Johnson JA, Burlew BS (1996) Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 24:350-355
53. Brøsen K (2004) Some aspect of genetic polymorphism in the biotransformation of antidepressant. Therapie 59:5-12
54. Patsalos PN (2005) Properties of antiepileptic drugs used in the treatment of generalized epiplepsies. Epilepsia 46(Suppl 9):140-148
55. Todd PA, Benfield P (1989) Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs 38:481-499
56. Bredberg U, Eyjolfsdottir GS, Paalzow L, Tfelt-Hansen P, Tfelt-Hansen V (1986) Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol 30:75-77
57. Cortelli P, Sacquegna T, Albani F, Baldrati A, D'Alessandro R, Baruzi A et al (1985) Propranolol plasma levels and relief of migraine: relationship between plasma propranolol and 4-hydroxypropranolol concentrations and clinical effects. Arch Neurol 42:46-48
58. Johnson JA, Zineh I, Bucket BJ, McCorray SP, Yarandi HN, Pauly DF (2003) Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metopolol. Clin Pharmacol Ther 74:44-52
59. Liu J, Liu Z-Q, Yu B-N, Xu F-H, Mo W, Zhou G et al (2006) β1 -Adrenoceptor receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 80:23-32
60. Schoenen J, Maertens de Noordhout A, Timsit- Berthier M, Timsit M (1986) Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia 6:229-233
61. Evans WE, Relling MV (1999) Pharmacogenomics: Translating functional genomics into rational therapy. Science 286:487-491